Op2Lysis

I’m pleased to share that I will be attending BioFIT 2024 in Lille. This event is a great opportunity to reconnect with the biotech community and exchange insights. I look forward to discussing recent developments and sharing positive updates about Op2Lysis as we continue to work on innovative solutions for cerebrovascular unmet medical needs. If you are attending as well, feel free to reach out—I’d be happy to connect. #BioFIT2024 #Networking #Biotech Op2Lysis

EACH Partners welcome the strong focus and commitment on cardiovascular health during yesterday's confirmation hearing of Commissioner-designate Várhelyi: "Related to the non‑communicable diseases – I mentioned the initiative that is very close to my heart, and that is the new initiative on European cardiovascular health. This is the single biggest health risk for Europeans. This is the health risk that we know the most about. And this is the health risk which is the most preventable. And this is related to obesity. This is related to diabetes. So I want to have a comprehensive plan, pretty much like the Cancer Plan which delivers for the patients on the ground." #CVHealthForAll

Presentation at the session on Rare and Orphan Diseases this afternoon 4:30 p.m. Join us! Christophe Gaudin #BioEUROPE

a follow up would be "what are the initiatives to tackle hemorrhagic stroke?" with a focus on TIPITCH Gaïa Zirka, PhD , Charlotte Cordonnier, sophie susen ! #TIPITICH: Transforming the Prognosis of Hemorrhagic Stroke! #RHU #FRANCE2030 #Innovation #unmetMedicalNeed ANR (Agence nationale de la recherche) CHU de Lille Op2Lysis

Today is #WorldStrokeDay   The theme of this year’s campaign is the power of sport. 🏃 🏊♀️ ⚽   Did you know that 1 million strokes each year are linked to physical inactivity?   Exercising frequently throughout your week helps reducing several stroke risk factors, including hypertension, diabetes, depression, stress and cholesterol.   Although today is the last day to participate in the #GreaterThan Global Challenge, that does not mean you need to stop exercising! 😉 Do you want to reduce your risk of stroke by 25%? Get active with your favorite exercise 5 times a week for 30 minutes and start reducing your risk right away!   Learn more about stroke on https://lnkd.in/ep6kBMT   #Stroke #CVD #CVHealthForAll #GreaterThanStroke European Stroke Organisation Stroke Alliance For Europe (SAFE)

What is hemorrhagic stroke, and what is the difference between ischemic and hemorrhagic stroke? How can pahtology be modeled in the R&D stages to foster the emergence of effective therapeutic strategies? How does Op2Lysis contribute to the hope that hemorrhagic stroke is a treatable condition? Here are some answers. Feel free to comment and share your thoughts #WolrdStrokeDay #Innovation #Translationality #ModelingDisease #OrphanDisease #IntracerebralHemorrhage #HemorrhagicStroke Op2Lysis

⚗️ See you soon in Stockholm for #BIOEuropeFall, the major autumn event dedicated to healthcare biotechnologies and the pharmaceutical industry 💊 📆 From November 4 to 6, 2024 , Wallonia will be present with 50 Belgian companies from the life sciences sector. 🎯 Belgium is recognized as a hub for biotechnology and pharmaceutical innovation, with a strong #ecosystem that includes world-class #research institutions, cutting-edge #technology platforms and a collaborative environment that supports the growth 📈 of start-ups and established companies. 🤝 Join us at booth #96 to learn more about our region's assets and explore #partnership opportunities with our companies. 💡 As a reminder, Wallonia has set up an unprecedented technological innovation partnership in the field of #ATMPs (Advanced Therapy Medicinal Products). With over 20 years' experience in these new-generation biomedicines, the Walloon region intends to establish itself as a European leader in this field. 👉 More info: https://lnkd.in/dQebeUXe #innovation #lifesciences #health #wallonia #invest #biotech Wallonia Export & Investment Agency BioWin Wallonia in Sweden Amyl Therapeutics Artialis Celyad Oncology CER Groupe convEyXO DeuterOncology NV Estetra EuroscreenFast EXO Biologics EyeD Pharma Hyloris Pharmaceuticals IDDI - Regulatory Statistics & Clinical Data Science Experts InhaTarget Therapeutics Op2Lysis Réseau LiEU RLM Consulting Seqalis Spectralys Biotech Syngulon THERAtRAME Univercells SA White Raven

Op2Lysis is excited to announce the receipt of public funding from the Normandy Region and the FEDER FSE+ FTJ Normandie program for its ThromboSTROKE collaborative project. Running from October 2024 to September 2027, the project aims to develop innovative models for ischemic stroke by addressing the critical challenge of clot heterogeneity. In collaboration with Inserm U1237, led by Professor Denis Vivien, Op2Lysis will focus on improving the translational relevance of preclinical models, with the goal of advancing stroke research and stimulating industrial developments. This project builds on Op2Lysis' expertise in translational models, which has already resulted in a 2023 Brain journal publication. 🚀 #StrokeResearch #Biotech #Innovation #Op2Lysis #FEDER #RégionNormandie Read the press release : https://lnkd.in/ezbvF35z

Congrès français d'hémostase 2024 à Lille. Une session hémorragie cérébrale sera l'occasion de présenter les avancées dans la modélisation de cette pathologie pour proposer de nouveaux traitements à ce besoin médical non satisfait! #cfh2024

🇺🇸 🇬🇧 Successful first toxicology study 🩸🧠   💥We are delighted to announce that the O2L-001 technology developed by Op2Lysis to treat massive and deep cerebral haemorrhage has reached a new milestone. The first "Dose Range Finding" safety study has produced very positive results. This success means that highly effective doses can be used in clinical trials.   PR available on our website : https://lnkd.in/eY8vjSGE -------------- 🇫🇷 Première étude toxicologique positive 🩸🧠   💥Nous avons le plaisir d'annoncer que la technologie O2L-001 développée par Op2Lysis pour traiter les hémorragies cérébrales massives et profondes vient de franchir un nouveau palier. La première étude de sécurité « Dose Range Finding" a donné des résultats très positifs. Ce succès permet de mieux envisager des doses très efficaces en essai clinique.